Dianne Spillman

575 total citations · 1 hit paper
8 papers, 387 citations indexed

About

Dianne Spillman is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Dianne Spillman has authored 8 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pathology and Forensic Medicine, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in Dianne Spillman's work include Lung Cancer Treatments and Mutations (3 papers), Autoimmune Bullous Skin Diseases (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Dianne Spillman is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Autoimmune Bullous Skin Diseases (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Dianne Spillman collaborates with scholars based in United States, Canada and Singapore. Dianne Spillman's co-authors include Julia A. Beaver, Richard Pazdur, Emily M. Haymes, Harpreet Singh, Nicole Drezner, Pallavi S. Mishra‐Kalyani, Emily Wearne, Hong Zhao, Jiang Liu and Youwei Bi and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Sports Medicine.

In The Last Decade

Dianne Spillman

7 papers receiving 376 citations

Hit Papers

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Me... 2021 2026 2022 2024 2021 50 100 150

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dianne Spillman United States 6 179 144 131 62 44 8 387
Karel Cwiertka Czechia 10 247 1.4× 115 0.8× 123 0.9× 108 1.7× 40 0.9× 45 436
Gustavo Ismael Belgium 6 296 1.7× 128 0.9× 55 0.4× 83 1.3× 32 0.7× 10 495
Herb Kotz United States 11 325 1.8× 148 1.0× 130 1.0× 86 1.4× 39 0.9× 23 494
Sundersingh Shirley India 8 116 0.6× 246 1.7× 65 0.5× 115 1.9× 44 1.0× 14 430
Yann Bergé France 10 162 0.9× 154 1.1× 100 0.8× 37 0.6× 18 0.4× 17 323
Dan Chan United States 6 287 1.6× 250 1.7× 194 1.5× 84 1.4× 36 0.8× 13 532
Hal Hirte Canada 8 149 0.8× 155 1.1× 45 0.3× 51 0.8× 49 1.1× 11 333
J. C. Bendell United States 13 208 1.2× 261 1.8× 82 0.6× 54 0.9× 53 1.2× 37 413
Heidi Nauwelaerts Switzerland 7 180 1.0× 228 1.6× 67 0.5× 62 1.0× 73 1.7× 14 342

Countries citing papers authored by Dianne Spillman

Since Specialization
Citations

This map shows the geographic impact of Dianne Spillman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dianne Spillman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dianne Spillman more than expected).

Fields of papers citing papers by Dianne Spillman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dianne Spillman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dianne Spillman. The network helps show where Dianne Spillman may publish in the future.

Co-authorship network of co-authors of Dianne Spillman

This figure shows the co-authorship network connecting the top 25 collaborators of Dianne Spillman. A scholar is included among the top collaborators of Dianne Spillman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dianne Spillman. Dianne Spillman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Vellanki, Paz J., Nicole Drezner, Xiaoxue Li, et al.. (2021). FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clinical Cancer Research. 27(24). 6638–6643. 42 indexed citations
2.
Nakajima, Erica C., Nicole Drezner, Xiaoxue Li, et al.. (2021). FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC. Clinical Cancer Research. 28(8). 1482–1486. 193 indexed citations breakdown →
3.
Vellanki, Paz J., Flora Mulkey, Lisa Rodríguez, et al.. (2021). FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review. Clinical Cancer Research. 27(13). 3522–3527. 41 indexed citations
4.
Arora, Shaily, Sanjeeve Balasubramaniam, Wei Zhang, et al.. (2020). FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis. Clinical Cancer Research. 26(19). 5062–5067. 63 indexed citations
5.
Spillman, Dianne, Shaily Arora, Rajesh Venugopal, et al.. (2020). FDA’s Oncology Center for Excellence Pilots Project Orbis: A framework for concurrent submission and review of oncology products among international partners.. Journal of Clinical Oncology. 38(15_suppl). e14125–e14125.
6.
Haymes, Emily M. & Dianne Spillman. (1989). Iron Status of Women Distance Runners, Sprinters, and Control Women. International Journal of Sports Medicine. 10(6). 430–433. 37 indexed citations
7.
Spillman, Dianne, et al.. (1988). Aprotinin inhibition of experimental pemphigus in Balb-c mice following passive transfer of pemphigus foliaceus serum. Clinical and Experimental Dermatology. 13(5). 321–327. 10 indexed citations
8.
Spillman, Dianne, et al.. (1984). [Bullous muco-synechial dermatitis atrophicans. Development and current nosological status].. PubMed. 12(5). 421–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026